A pharmacodynamic and pharmacokinetic comparison of intravenous quinaprilat and oral quinapril.

Abstract:

:Quinaprilat is the active metabolite of quinapril, an orally active angiotensin-converting enzyme (ACE) inhibitor. The dose-response and duration-of-effect after single intravenous doses of quinaprilat and placebo (part A) and after administration of oral quinapril solution and intravenous quinaprilat (part B) were assessed in a randomized, crossover study of two groups of 12 healthy volunteers. Pharmacodynamic effects of quinaprilat and oral quinapril were assessed by measurement of blood pressure changes after an infusion of angiotensin I (A-I) at a dose previously determined to produce an increase in diastolic blood pressure of 25 mmHg under standardized conditions (A-I pressor response). A clear dose-response relationship was demonstrated for quinaprilat in this pharmacodynamic model, with 0.5 mg as the lowest effective dose. Doses of 1.0 mg and higher partially suppressed A-I pressor response for at least 6 hours. Onset of action was observed within 15 minutes of intravenous administration of quinaprilat and was independent of dose, whereas peak effect and duration of action appeared to be dose related. Quinaprilat doses of 2.5 mg and 10 mg achieved approximately 50% and > 80% inhibition of the A-I pressor response, respectively. In part B, these doses of intravenous quinaprilat were compared with oral doses of quinapril previously found to produce 50% (2.5 mg) and 90% (10 mg) inhibition of the A-I pressor response. The magnitude of effect was similar after administration of 20 mg quinapril orally and 10 mg quinaprilat intravenously. Duration of action was longer, however, after administration of intravenous quinaprilat (10 mg) than after oral quinapril (20 mg), due to the higher maximum plasma concentration (Cmax) of quinaprilat. Mean area under the plasma concentration-time curve extrapolated to infinity (AUC0-infinity) of quinaprilat was similar after the 10-mg dose of intravenous quinaprilat and the 20-mg dose of oral quinapril. Based on the concentrations of quinaprilat observed in this study, the absolute bioavailability of quinapril was approximately 50%; intravenous quinaprilat should therefore produce a pharmacodynamic response similar to that obtained with oral quinapril at approximately half the dose.

journal_name

J Clin Pharmacol

authors

Breslin E,Posvar E,Neub M,Trenk D,Jahnchen E

doi

10.1002/j.1552-4604.1996.tb05028.x

subject

Has Abstract

pub_date

1996-05-01 00:00:00

pages

414-21

issue

5

eissn

0091-2700

issn

1552-4604

journal_volume

36

pub_type

临床试验,杂志文章,随机对照试验
  • Aprepitant pharmacokinetics and assessing the impact of aprepitant on cyclophosphamide metabolism in cancer patients undergoing hematopoietic stem cell transplantation.

    abstract::Aprepitant, a neurokinin antagonist, is an effective antiemetic agent in chemotherapy for delayed nausea and vomiting. The study objective was to evaluate the pharmacokinetics of aprepitant and concurrent cyclophosphamide (CY), often a component of hematopoietic stem cell transplant (HSCT) conditioning regimen, in can...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1177/0091270011398243

    authors: Bubalo JS,Cherala G,McCune JS,Munar MY,Tse S,Maziarz R

    更新日期:2012-04-01 00:00:00

  • Clinical significance of methohexital, meperidine, and diazepam in breast milk.

    abstract::Concentrations in breast milk of medications used during general anesthesia were measured to determine whether interruption of breast-feeding was indicated. Breast milk and maternal blood samples were obtained from nine women undergoing tubal sterilization under general anesthesia. Concentrations of methohexital, mepe...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/j.1552-4604.1997.tb04780.x

    authors: Borgatta L,Jenny RW,Gruss L,Ong C,Barad D

    更新日期:1997-03-01 00:00:00

  • Significance of classifying antiarrhythmic actions since the cardiac arrhythmia suppression trial.

    abstract::The Cardiac Antiarrhythmic Suppression Trial (CAST) showed flecainide and encainide induced excess mortality compared with placebo. Labeling drugs as Class 1C is based on clinical observations, comprising measurements of the electrocardiographic parameters QRS. H-V and J-T intervals and of effective refractory period ...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1002/j.1552-4604.1991.tb03695.x

    authors: Vaughan Williams EM

    更新日期:1991-02-01 00:00:00

  • Pharmacokinetics of desmopressin administrated as an oral lyophilisate dosage form in children with primary nocturnal enuresis and healthy adults.

    abstract::The population pharmacokinetics of desmopressin in children with nocturnal enuresis and in healthy adults were compared using a 1-compartment model with first-order absorption and first-order elimination. In addition, the model consisted of a number of transit compartments before absorption to describe a lag-time. The...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1177/0091270006291838

    authors: Osterberg O,Savic RM,Karlsson MO,Simonsson US,Nørgaard JP,Walle JV,Agersø H

    更新日期:2006-10-01 00:00:00

  • Pleiotropic effects of atorvastatin on monocytes in atherosclerotic patients.

    abstract::The objective of this study was to investigate the gene expression signature of monocyte/macrophages and the pleiotropic effects of atorvastatin on monocytes in atherosclerotic patients. Forty patients with coronary heart diseases were randomly assigned to double-blind therapy with either 20 or 80 mg per day of atorva...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1177/0091270009340889

    authors: Wang ZH,Liu XL,Zhong M,Zhang LP,Shang YY,Hu XY,Li L,Zhang Y,Deng JT,Zhang W

    更新日期:2010-03-01 00:00:00

  • The relation of anticonvulsant drug levels to complete seizure control.

    abstract::This study was undertaken to determine the relationship of serum ACD levels to dosage in a group of patients who had been seizure free for at least two years. It demonstrated that some patients remain completely seizure free with DPH and/or phenobarbital serum concentrations which are well below the reported "optimal"...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1002/j.1552-4604.1976.tb01491.x

    authors: Feldman RG,Pippenger CE

    更新日期:1976-01-01 00:00:00

  • Drug-drug and drug-food interactions between tenofovir disoproxil fumarate and didanosine.

    abstract::The drug-drug and drug-food interactions between tenofovir DF and didanosine EC were evaluated in 2 pharmacokinetic studies in healthy adult subjects. When 400 mg was dosed with tenofovir DF, mean didanosine AUC was increased by 44% to 60% following fasted or fed administration. Staggered coadministration (2 hour, fas...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1177/0091270005281351

    authors: Kearney BP,Sayre JR,Flaherty JF,Chen SS,Kaul S,Cheng AK

    更新日期:2005-12-01 00:00:00

  • The expanding role of angiotensin converting enzyme inhibitors in the management of hypertension.

    abstract::Angiotensin converting enzyme (ACE) inhibitors are increasingly important in antihypertensive therapy because of their efficacy, tolerability, and specific benefits in subsets of patients. They are pharmacologically diverse. Whereas most benefits have been proven with older agents (captopril, enalopril), newer agents,...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1002/j.1552-4604.1995.tb04070.x

    authors: Burris JF

    更新日期:1995-04-01 00:00:00

  • Pharmacokinetics, pharmacodynamics, and safety of microencapsulated octreotide acetate in healthy subjects.

    abstract::The pharmacokinetics, pharmacodynamics, and safety of the marketed formulation of microencapsulated octreotide acetate were evaluated in an open-label study in 22 healthy cholecystectomized subjects. Each subject received a single 30 mg dose of microencapsulated octreotide acetate intramuscularly (i.m.). Concentration...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1177/00912700022009242

    authors: Chen T,Miller TF,Prasad P,Lee J,Krauss J,Miscik K,Kalafsky G,McLeod JF

    更新日期:2000-05-01 00:00:00

  • Grapefruit-drug interactions: can interactions with drugs be avoided?

    abstract::Grapefruit is rich in flavonoids, which have been demonstrated to have a preventive influence on many chronic diseases, such as cancer and cardiovascular disease. However, since the early 1990s, the potential health benefits of grapefruit have been overshadowed by the possible risk of interactions between drugs and gr...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1177/0091270006294277

    authors: Mertens-Talcott SU,Zadezensky I,De Castro WV,Derendorf H,Butterweck V

    更新日期:2006-12-01 00:00:00

  • Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects.

    abstract::Atazanavir, a potent protease inhibitor of human immunodeficiency virus (HIV), exhibits pH-dependent solubility. Previous studies have indicated that coadministration with omeprazole 40 mg once daily significantly decreased atazanavir exposure by approximately 75%. Concomitant use of omeprazole and atazanavir is curre...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1177/0091270010367651

    authors: Zhu L,Persson A,Mahnke L,Eley T,Li T,Xu X,Agarwala S,Dragone J,Bertz R

    更新日期:2011-03-01 00:00:00

  • Short-term effects of cannabinoids on immune phenotype and function in HIV-1-infected patients.

    abstract::Cannabinoids, including smoked marijuana and delta9-tetrahydrocannabinol (THC) (dronabinol, Marinol), have been used to treat human immunodeficiency virus-1 (HIV)-associated anorexia and weight loss. Concerns have been raised, however, that these compounds might have adverse effects on the immune system of subjects wi...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1002/j.1552-4604.2002.tb06007.x

    authors: Bredt BM,Higuera-Alhino D,Shade SB,Hebert SJ,McCune JM,Abrams DI

    更新日期:2002-11-01 00:00:00

  • Clinical consequences of marijuana.

    abstract::As documented in national surveys, for the past several years, marijuana has been the most commonly abused drug in the United States, with approximately 6% of the population 12 years and older having used the drug in the month prior to interview. The use of marijuana is not without significant health hazards. Marijuan...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/j.1552-4604.2002.tb05997.x

    authors: Khalsa JH,Genser S,Francis H,Martin B

    更新日期:2002-11-01 00:00:00

  • Plasma kinetics, metabolism, and urinary excretion of alpha-lipoic acid following oral administration in healthy volunteers.

    abstract::R(+)-alpha-lipoic acid is a natural occurring compound that acts as an essential cofactor for certain dehydrogenase complexes. The redox couple alpha-lipoic acid/dihydrolipoic acid possesses potent antioxidant activity. Exogenous racemic alpha-lipoic acid orally administered for the symptomatic treatment of diabetic p...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1177/0091270003258654

    authors: Teichert J,Hermann R,Ruus P,Preiss R

    更新日期:2003-11-01 00:00:00

  • An evaluation of the dose-dependent inhibition of CYP1A2 by rofecoxib using theophylline as a CYP1A2 probe.

    abstract::This study was undertaken to determine whether rofecoxib can interfere with CYP1A2 activity in humans using theophylline as a probe substrate. Single oral doses of theophylline were administered to each of three panels of 12 healthy subjects receiving daily doses of rofecoxib for 7 days to examine the effect of rofeco...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1177/0091270003257454

    authors: Bachmann K,White D,Jauregui L,Schwartz JI,Agrawal NG,Mazenko R,Larson PJ,Porras AG

    更新日期:2003-10-01 00:00:00

  • Tissue penetration of cefpodoxime and cefixime in healthy subjects.

    abstract::Microdialysis is a technique that allows the measurement of free antibiotic concentrations in different tissues, which are responsible for the antibacterial activity at the infection site. In an open, randomized, 2-way crossover study in healthy volunteers, the muscle penetration of orally administered cefpodoxime (40...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1177/0091270004273679

    authors: Liu P,Müller M,Grant M,Obermann B,Derendorf H

    更新日期:2005-05-01 00:00:00

  • Intense surveillance of adverse drug reactions. An analysis of 338 patients.

    abstract::A prospective study of adverse drug reactions was recently completed at the Clinical Pharmacology Unit of J. J. Group of Hospitals. 338 patients were included in this study, and adverse reactions were noted by a team of workers including a nurse and a physician. World Health Organization definitions were used to descr...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/j.1552-4604.1975.tb02365.x

    authors: Vakil BJ,Kulkarni RD,Chabria NL,Chadha DR,Deshpande VA

    更新日期:1975-05-01 00:00:00

  • Effect of a new beta-adrenergic blocker, l-bunolol, on blood pressure and on the renin-aldosterone system.

    abstract::The antihypertensive effect of a new beta-adrenergic receptor blocker, l-bunolol, was evaluated in 11 hospitalized hypertensive patients of whom four belonged to the high-renin, five to the normal-renin, and two to the low-renin subgroup. There was a significant decrease in blood pressure in most patients, often to no...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1002/j.1552-4604.1977.tb04615.x

    authors: Gavras H,Gavras I,Brunner HR,Laragh JH

    更新日期:1977-05-01 00:00:00

  • Investigation of safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of a long-acting α-MSH analog in healthy overweight and obese subjects.

    abstract::MC4-NN2-0453 is a novel, long-acting, selective, melanocortin-4-receptor agonist developed for treatment of obesity. This first-human-dose, randomized, double-blind, placebo-controlled trial investigated the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of MC4-NN2-0453 in ov...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1002/jcph.211

    authors: Royalty JE,Konradsen G,Eskerod O,Wulff BS,Hansen BS

    更新日期:2014-04-01 00:00:00

  • Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment.

    abstract::Precision medicine in oncology is the result of an increasing awareness of patient-specific clinical features coupled with the development of genomic-based diagnostics and targeted therapeutics. Companion diagnostics designed for specific drug-target pairs were the first to widely utilize clinically applicable tumor b...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1002/jcph.765

    authors: Schmidt KT,Chau CH,Price DK,Figg WD

    更新日期:2016-12-01 00:00:00

  • Population pharmacokinetic modeling and simulation of amprenavir following fosamprenavir/ritonavir administration for dose optimization in HIV infected pediatric patients.

    abstract::Fosamprenavir (FPV) is the phosphate ester prodrug of the HIV-1 protease inhibitor amprenavir (APV). A pediatric population pharmacokinetic model for APV was developed and simulation was used to identify dosing regimens for pediatric patients receiving FPV in combination with ritonavir (RTV) which resulted in concentr...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/jcph.205

    authors: Barbour AM,Gibiansky L,Wire MB

    更新日期:2014-02-01 00:00:00

  • Nalmefene: safety and kinetics after single and multiple oral doses of a new opioid antagonist.

    abstract::The aim of these two studies was to evaluate the safety and pharmacokinetics of oral nalmefene, a new orally effective opioid antagonist. In the first study, single ascending doses of 50, 100, 200, and 300 mg of nalmefene HCl were administered in double-blind fashion to four groups of healthy men. There were six subje...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1002/j.1552-4604.1987.tb02191.x

    authors: Dixon R,Gentile J,Hsu HB,Hsiao J,Howes J,Garg D,Weidler D

    更新日期:1987-03-01 00:00:00

  • Pharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 Trial.

    abstract::In the pivotal TEMPO 3:4 trial, the arginine vasopressin V2-receptor antagonist tolvaptan reduced the rate of kidney growth in patients with autosomal dominant polycystic kidney disease. Tolvaptan was initiated as daily morning/afternoon doses of 45/15 mg, and uptitrated weekly to 60/30 mg and 90/30 mg according to pa...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,多中心研究

    doi:10.1002/jcph.880

    authors: Shoaf SE,Chapman AB,Torres VE,Ouyang J,Czerwiec FS

    更新日期:2017-07-01 00:00:00

  • Review of UCN-01 development: a lesson in the importance of clinical pharmacology.

    abstract::UCN-01 is a protein kinase inhibitor under development as a novel anticancer drug. The initial pharmacologic features in patients were not predicted from preclinical experiments. The distribution volume and the systemic clearance were much lower than those in experimental animals (mice, rats, and dogs), and the elimin...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1177/0091270005274549

    authors: Fuse E,Kuwabara T,Sparreboom A,Sausville EA,Figg WD

    更新日期:2005-04-01 00:00:00

  • Pomegranate juice does not impair clearance of oral or intravenous midazolam, a probe for cytochrome P450-3A activity: comparison with grapefruit juice.

    abstract::The effect of pomegranate juice (PJ) or grapefruit juice (GFJ) on CYP3A activity was studied in vitro and in healthy human volunteers. In human liver microsomes, the mean 50% inhibitory concentrations (IC(50)) for PJ and GFJ versus CYP3A (triazolam alpha-hydroxylation) were 0.61% and 0.55%, (v/v) respectively, without...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1177/0091270006298359

    authors: Farkas D,Oleson LE,Zhao Y,Harmatz JS,Zinny MA,Court MH,Greenblatt DJ

    更新日期:2007-03-01 00:00:00

  • Lofexidine in the treatment of hypertension: a twice-daily versus one-daily dose comparison with 24-hour blood pressure monitoring.

    abstract::Lofexidine, an antihypertensive imidazoline derivative, was given to ten hypertensives on both a twice-daily and once-daily regimen, using routine blood pressure measurements and 24-hour Remler recording. Plasma renin activity and catecholamines were measured. After a dose titration with twice-daily doses, the total t...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/j.1552-4604.1981.tb05697.x

    authors: Garrett BN,Kaplan NM

    更新日期:1981-04-01 00:00:00

  • Antiarrhythmic drug therapy for suppression of ventricular arrhythmia: experience with 122 patients treated for two years.

    abstract::Although there are many reports of the short-term effectiveness of antiarrhythmic drugs for suppression of ventricular ectopic depolarizations, there are less data available on the long-term use of these drugs. We treated 122 patients for up to 2 years with antiarrhythmic drugs for suppression of frequent ventricular ...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/j.1552-4604.1990.tb03466.x

    authors: Salerno DM,Fifield J,Hodges M

    更新日期:1990-03-01 00:00:00

  • Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics.

    abstract::The purpose of this study was to characterize the effect of potent CYP2D6 inhibition byparoxetine on atomoxetine disposition in extensive metabolizers. This was a single-blind, two-period, sequential studyin 22 healthy individuals. In period 1, 20 mg atomoxetine bid was administered to steady state. In period 2, 20 mg...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1177/009127002762491307

    authors: Belle DJ,Ernest CS,Sauer JM,Smith BP,Thomasson HR,Witcher JW

    更新日期:2002-11-01 00:00:00

  • Pharmacokinetics, safety, and tolerability of the oral Renin inhibitor aliskiren in patients with hepatic impairment.

    abstract::Aliskiren is the first in a new class of orally active, direct renin inhibitors for the treatment of hypertension. This open-label, nonrandomized, single-center, parallel-group study compared the pharmacokinetics and safety of a single 300-mg oral dose of aliskiren in patients with mild, moderate, or severe hepatic im...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1177/0091270006294404

    authors: Vaidyanathan S,Warren V,Yeh C,Bizot MN,Dieterich HA,Dole WP

    更新日期:2007-02-01 00:00:00

  • Nonsteroidal antiinflammatory drug modulation of behavioral responses to intrathecal N-methyl-D-aspartate, but not to substance P and amino-methyl-isoxazole-propionic acid in the rat.

    abstract::Antinociception by nonsteroidal antiinflammatory drugs, notably diclofenac and S(+)-ibuprofen, has traditionally been attributed to peripheral tissue cyclooxygenase inhibition. This study investigates the potential role of the nitric oxide system for the central antinociceptive effects of diclofenac, S(+)-, and R(-)-i...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:

    authors: Björkman R,Hallman KM,Hedner J,Hedner T,Henning M

    更新日期:1996-12-01 00:00:00